Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycystic Ovary Syndrome 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammation 1Hyperandrogenism 1Anovulation 1

Interventions

fludarabine phosphate 87Cyclophosphamide 78Whole-Body Irradiation 59Azacitidine 59fludarabine 56Mycophenolic Acid 56Busulfan 53Tacrolimus 51Peripheral Blood Stem Cell Transplantation 41Melphalan 40Cytarabine 38Antilymphocyte Serum 38Filgrastim 37Granulocyte Colony-Stimulating Factor 33Cyclosporine 33Methotrexate 32Decitabine 32thymoglobulin 22Thiotepa 21Clofarabine 21Cord Blood Stem Cell Transplantation 19Stem Cell Transplantation 16Alemtuzumab 16Sirolimus 15Rituximab 15sargramostim 12Lenalidomide 12Etoposide 11Radiotherapy 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myelodysplastic Syndromes × salicylsalicylic acid × Clear all
NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Rutgers, The State University of New Jersey

Phase 2 Completed
5 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡